MCID: TRN018
MIFTS: 56

Transitional Cell Carcinoma malady

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Transitional Cell Carcinoma

About this section

Aliases & Descriptions for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 11 46 13
Carcinoma, Transitional Cell 37 66
Transitional Cell Neoplasm 11 66
Transitional Cell Carcinoma of Bladder 66
 
Carcinoma Transitional Cell 48
Urothelial Cell Carcinoma 11
Transitional Cell Tumor 11
Transitional Carcinoma 11

Classifications:



External Ids:

Disease Ontology11 DOID:2671
MeSH37 D002295
NCIt43 C2930, C6783

Summaries for Transitional Cell Carcinoma

About this section
Wikipedia:69 Transitional cell carcinoma (TCC, also urothelial cell carcinoma or UCC) is a type of cancer that... more...

MalaCards based summary: Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to kidney pelvis sarcomatoid transitional cell carcinoma and fallopian tube carcinoma, and has symptoms including genitourinary symptoms An important gene associated with Transitional Cell Carcinoma is UPK2 (Uroplakin 2), and among its related pathways are Adherens junction and Thyroid cancer. Affiliated tissues include kidney, prostate and lymph node, and related mouse phenotypes are respiratory system and integument.

Disease Ontology:11 A carcinoma that derives from transitional epithelial cells.

Related Diseases for Transitional Cell Carcinoma

About this section

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 345)
idRelated DiseaseScoreTop Affiliating Genes
1kidney pelvis sarcomatoid transitional cell carcinoma34.4EGFR, ERBB2
2fallopian tube carcinoma30.9CDH1, CDKN2A, TP53
3herpes simplex30.3CDKN2A, EGFR, TP53
4papilloma29.9CEACAM5, HRAS, KRT20, KRT7
5renal cell carcinoma29.6CDH1, EGFR, IFNA2, KRT20, KRT7
6plasmacytoma28.0CDH1, CDKN2A, CEACAM5, EGFR, ERBB2, KRT20
7lung cancer27.2CDH1, CDKN2A, CEACAM5, EGFR, ERBB2, HRAS
8sarcomatoid transitional cell carcinoma12.4
9prostate transitional cell carcinoma12.2
10ovary transitional cell carcinoma12.2
11ureter transitional cell carcinoma12.2
12invasive bladder transitional cell carcinoma12.2
13renal pelvis transitional cell carcinoma12.2
14fallopian tube transitional cell carcinoma12.2
15non-papillary transitional cell carcinoma of the bladder12.1
16bartholin's gland transitional cell carcinoma12.1
17endometrial transitional cell carcinoma12.1
18transitional cell carcinoma of the corpus uteri12.1
19bladder papillary transitional cell neoplasm12.1
20urethra transitional cell carcinoma12.1
21urinary tract non-invasive transitional cell neoplasm12.0
22infiltrating renal pelvis transitional cell carcinoma12.0
23infiltrating ureter transitional cell carcinoma12.0
24papillary transitional carcinoma11.5
25urinary bladder urothelial carcinoma11.3
26oral tuberculosis10.9CDH1, TP53
27cystinosis, nephropathic10.9ERBB2, TP53
28peptic ulcer disease10.8EGFR, TP53
29pregnancy adenoma10.8CDH1, ERBB2
30pasli disease10.8FGFR3, TP53
31renal pelvis inverted papilloma10.7CDH1, TP53
32animal phobia10.7EGFR, ERBB2, TP53
33infiltrating lipoma10.7PTGS2, TP53
34ovarian small cell carcinoma10.7EGFR, ERBB2, TP53
35familial renal oncocytoma10.7FGFR3, TP53, UPK3A
36salivary gland adenoid cystic carcinoma10.7CDKN2A, TP53
37distal monosomy 9p10.7EGFR, ERBB2, TP53
38lobular neoplasia10.7CDH1, ERBB2, TP53
39extrahepatic bile duct adenocarcinoma10.7CDH1, KRT20, TP53
40giant cell myocarditis10.7CDH1, KRT20
41her2-receptor negative breast cancer10.7EGFR, ERBB2
42skeletal tuberculosis10.7CDKN2A, ERBB2
43vulval paget's disease10.7ERBB2, KRT20, TP53
44progesterone-receptor positive breast cancer10.7EGFR, ERBB2, TP53
45early congenital syphilis10.7EGFR, ERBB2, HRAS
46median neuropathy10.6EPHB2, TP53
47cerebellar vermis medulloblastoma10.6CDH1, EGFR, TP53
48cervical serous adenocarcinoma10.6ERBB2, TP53
49brain glioblastoma multiforme10.6UPK1A, UPK2, UPK3A
50blepharochalasis10.6EGFR, ERBB2, TP53

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to transitional cell carcinoma

Symptoms for Transitional Cell Carcinoma

About this section

UMLS symptoms related to Transitional Cell Carcinoma:


genitourinary symptoms

Drugs & Therapeutics for Transitional Cell Carcinoma

About this section

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 155)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DocetaxelApproved May 1996Phase 3, Phase 2, Phase 11880114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
2
LapatinibApproved March 2007Phase 2, Phase 3, Phase 1296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
3
DoxilApproved June 1999Phase 3, Phase 2, Phase 1167631703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
4
FluorouracilPhase 3, Phase 2172851-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
5pancreatic polypeptidePhase 3, Phase 120
6
FentanylPhase 3739437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
7
EflornithinePhase 33570052-12-93009
Synonyms:
(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid
.alpha.-DFMO HCl
2,5-diamino-2-(difluoromethyl)pentanoic acid
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrate hydrochloride
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride
2-(Difluoromethyl)-DL-ornithine
2-(Difluoromethyl)-DL-ornithine HCl
2-(Difluoromethyl)-DL-ornithine hydrochloride
2-(Difluoromethyl)-DL-ornithine monohydrochloride
2-(Difluoromethyl)-DL-ornithine monohydrochloride, monohydrate
2-(Difluoromethyl)-DL-ornithine monohydrochloride.monohydrate
2-(Difluoromethyl)ornithine
2-(Difluoromethyl)ornithine hydrochloride hydrate
67037-37-0
68278-23-9
70050-56-5
70052-12-9
70052-12-9 (Parent)
96020-91-6
96020-91-6 (mono-hydrochloride, monohydrate)
AC-388
AC-5497
AC1L1EYW
AC1L1M41
AC1L9B1G
BMS 203522
BRN 2250529
C07997
C6H12F2N2O2.HCl.H2O
CCRIS 3295
CCRIS 3718
CCRIS 5805
CHEBI:41948
CHEMBL1201037
CHEMBL536971
CID3009
CID441361
CID57004
CPP-1X
D,L-alpha-Difluoromethylornithine
D,L-alpha-Difluoromethylornithine hydrochloride
D00829
D07883
D193_SIGMA
DFMO
DFMO (growth regulator)
DFMO HCl
DFMO hydrochloride
DFMO hydrochloride hydrate
DL-.alpha.-Difluoromethylornithine
DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride
DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate
DL-alpha-(Difluoromethyl)ornithine
DL-alpha-Difluoromethylornithine
DL-alpha-Difluoromethylornithine hydrochloride
 
DL-alpha-Difluoromethylornithine hydrochloride hydrate
DL-alpha-Difluoromethylornithine, Hydrochloride
Difluoromethylornithine
Difluromethylornithine
EFLORNITHINE
EFLORNITHINE HYDROCHLORIDE
EINECS 269-532-0
EU-0100429
Eflornithine (INN)
Eflornithine HCl
Eflornithine [INN:BAN]
Eflornithine hydrochloride (USAN)
Eflornithine hydrochloride [USAN]
Eflornithine hydrochloride hydrate
Eflornithine hydrochloride monohydrate
Eflornithinum
Eflornithinum [Latin]
Eflornitina
Eflornitina [Spanish]
FT-0082608
FT-0082826
HSCI1_000267
I06-0316
I06-0530
LS-178282
LS-185084
LS-7332
LS-98405
Lopac0_000429
MDL 71,782 A
MDL 71782
MDL-71782A
MLS000069341
MLS001332583
MolPort-003-940-991
N-Difluoromethylornithine
NCGC00015316-03
NCGC00093850-01
NCGC00162152-01
NSC270295
NSC337250
Ornidyl
Ornidyl (TN)
Ornithine, 2-(difluoromethyl)-, monohydrochloride
RMI 71782
RMI-71782
SBB066102
SMR000058442
UNII-4NH22NDW9H
UNII-ZQN1G5V6SR
Vaniqa
alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid
alpha-(Difluoromethyl)-DL-ornithine
alpha-Difluoromethylornithine
alpha-Difluoromethylornithine hydrochloride
dfmo
α-difluoromethylornithine
8
ramucirumabPhase 3, Phase 2, Phase 168947687-13-0
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
9
CisplatinPhase 2, Phase 3, Phase 1261415663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
10
GefitinibPhase 3, Phase 2345184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
11
ValrubicinPhase 3, Phase 2, Phase 1956124-62-041744
Synonyms:
(2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate
(2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester
(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8²-valerate
(8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate
136816-53-0
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
56124-62-0
AC1L26EA
AD 32
Adriamycin, trifluoroacetyl-, 14-valerate
Antibiotic AD 32
Antibiotic Ad 32
C34H36F3NO13
CHEMBL20225
CID41744
D02697
DB00385
HSDB 7288
I06-1096
 
LS-15286
N-Trifluoroacetyladriamycin 14-valerate
N-Trifluoroacetyladriamycin-14-valerate
N-Trifluoroacetyldoxorubicin 14-valerate
NCI60_001970
NSC 246131
NSC-246131
NSC246131
Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
Trifluoroacetyladriamycin-14-valerate
UNII-2C6NUM6878
Valrubicin
Valrubicin (USP/INN)
Valrubicin [USAN]
Valrubicina
Valrubicine
Valrubicinum
Valstar
Valstar (TN)
Valstar Preservative Free
[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
12interferonsPhase 2, Phase 3, Phase 12112
13Alkylating AgentsPhase 3, Phase 2, Phase 1, Phase 04573
14topoisomerase I inhibitorsPhase 2, Phase 31313
15
seleniumPhase 31717782-49-2
Synonyms:
Selanediide
Selenide
 
Selenide(2-)
Selenium
Selenium ion (Se2+)
16lenograstimPhase 3, Phase 2, Phase 11178
17
MethotrexatePhase 3, Phase 214961959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
18
BevacizumabPhase 3, Phase 2, Phase 11938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
19
PaclitaxelPhase 3, Phase 2, Phase 1269133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
20
FenretinidePhase 34265646-68-6
Synonyms:
4-HPR
 
4-hydroxy(phenyl)retinamide
N-(4-Hydroxyphenyl)All-Trans Retinamide
21
Aminolevulinic acidPhase 3150106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
22
Levulinic acidPhase 34123-76-211579
Synonyms:
3-Acetylpropionate
3-Acetylpropionic acid
4-Ketovalerate
4-Ketovaleric acid
4-Oxopentanoate
4-Oxopentanoic acid
4-Oxovalerate
4-Oxovaleric acid
Laevulinate
Laevulinic acid
 
Levulate
Levulic acid
Levulinate
Levulinic acid
b-Acetylpropionate
b-Acetylpropionic acid
beta-Acetylpropionate
beta-Acetylpropionic acid
g-Ketovalerate
g-Ketovaleric acid
gamma-Ketovalerate
gamma-Ketovaleric acid
23
GemcitabinePhase 2, Phase 3, Phase 1192895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
24
VinblastinePhase 2, Phase 3, Phase 1398865-21-413342, 241903
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC-20335
AC1L21JC
AC1L68D2
AC1MXZJ2
BIDD:PXR0201
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
Bio-0111
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
 
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NCI-C04842
NCI60_004200
NChemBio.2007.10-comp22
NDC 0002-1452-01
NSC 47842
Neuro_000020
Nincaluicolflastine
Rozevin
SPBio_000680
STOCK1N-38480
Spectrum2_000890
Spectrum3_001994
UNII-5V9KLZ54CY
VLB
VR-8
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [DCIT]
Vinblastina [Dcit]
Vinblastine
Vinblastine (INN)
Vinblastine Sulfate
Vinblastine [INN:BAN]
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
nchembio873-comp22
vinblastine
25
DoxorubicinPhase 3, Phase 2, Phase 1167623214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
26
CarboplatinPhase 3, Phase 2, Phase 1194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
27
succinylcholinePhase 3, Phase 2, Phase 1154306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
28taxanePhase 3, Phase 2335
29
OlaparibPhase 2, Phase 3117763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
30
nivolumabPhase 3, Phase 2, Phase 1254946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
31
TopotecanPhase 2, Phase 3336119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
32
Maleic acidPhase 2, Phase 3292110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
33
CediranibPhase 2, Phase 3919933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
34
pembrolizumabPhase 3, Phase 2, Phase 13551374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
35
Amphotericin BPhase 2, Phase 31171397-89-314956, 5280965
Synonyms:
12633-72-6
1397-89-3
30782-62-8
5-18-10-00525 (Beilstein Handbook Reference)
54482-28-9
8055-20-7
AB00513832
ABLC
AC1L1CN2
AC1L24V6
AC1L70KF
AC1L73U6
AC1NQXTD
AC1NTQ32
AC1NUQG4
AC1NY9JC
AC1O7GCZ
AC1O8FQV
AC1O8PFK
AI3-26528
AMPH-B
AMPH-b
Abelcet
Abelecet
AmBisome (TN)
Ambap1397-89-3
Ambisome
Amfotericina B
Amfotericina B [INN-Spanish]
Ampho-Moronal
Amphocin
Amphomoronal
Amphortericin B
Amphotec
Amphotec (TN)
Amphotericin
Amphotericin .BETA.
Amphotericin B
Amphotericin B (JP15/USP/INN)
Amphotericin B Cholesterol Dispersion
Amphotericin B Colloidal Dispersion
Amphotericin B [USAN:INN:JAN]
Amphotericin B, Lipid-based
Amphotericin B, Streptomyces sp.
Amphotericin-B
Amphotericine B
Amphotericine B [INN-French]
Amphotericinum
Amphotericinum B
Amphotericinum B [INN-Latin]
Amphotherizin
Amphotherizin [German]
Amphotéricine B
Amphozone
BIDD:GT0351
BPBio1_000374
BRN 0078342
BSPBio_000340
C-AmB
C06573
C47H73NO17
CCRIS 5963
CHEBI:2682
CHEMBL1200646
CHEMBL267345
CID10533925
CID10629638
CID10677275
CID14956
CID1972
 
CID352546
CID354192
CID5280965
CID5386092
CID5458486
CID5771695
CID6604295
CID6708817
CID6713692
CID9919339
D00203
DB00681
DivK1c_007045
EINECS 215-742-2
Fungilin
Fungisome
Fungisone
Fungizone
Fungizone (TN)
HMS1569A22
HSDB 3008
HSDB 3008 IAB
Halizon
I06-0257
KBio1_001989
KBio2_000551
KBio2_003119
KBio2_005687
KBioGR_002298
KBioSS_000551
LMPK06000002
LNS-AmB
LS-187721
LS-93
Liposomal Amphotericin B
Liposomal amphotericin b
MLS002702966
MolPort-006-392-260
Mysteclin-F
NCGC00014913
NCGC00090808-01
NCGC00098014-01
NCGC00179595-01
NCI527017
NCI60_004288
NCIStruc1_001042
NCIStruc2_000920
NKTR-024
NS 718
NSC 527017
NSC-527017
NSC527017
Prestwick0_000410
Prestwick1_000410
Prestwick2_000410
Prestwick3_000410
Prestwick_721
SMP1_000302
SMR001566780
SPBio_000715
SPBio_002279
ST50999656
SinuNase
SpecPlus_000949
Spectrum2_000818
Spectrum4_001779
Spectrum_000111
UNII-7XU7A7DROE
amophotericin B
amphotericin B liposomal
amphotericin b
36
MannitolPhase 3, Phase 225769-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
37
ApaziquonePhase 39114560-48-45813717
Synonyms:
(E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione
114560-48-4
3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol
5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione
5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione
AC1NXQZI
Apaziquone
Apaziquone (USAN/INN)
Apaziquone [USAN:INN]
Apaziquonum
Apaziquonum [INN-Latin]
C060817
C15H16N2O4
CHEMBL73822
CID5813717
D02965
E 09
E-09
 
E-85/050
E-85/053
E09
EO 9
EO 9 (pharmaceutical)
EO-9
EO9
EOquin
Eoquin (TN)
LS-83017
MolPort-005-942-580
NOR-701
NSC 382,459
NSC 382456
NSC 382459
NSC-382456
NSC-382459
Neoquin
UNII-H464ZO600O
ZINC01536777
38
CephalexinPhase 34915686-71-227447
Synonyms:
(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
105879-42-3 (mono-hydrochloride, mono-hydrate)
105879-42-3 (mono-hydrochloride,mono-hydrate)
14101-75-8
15686-71-2
15686-71-2 (Parent)
17692-47-6
23325-78-2
23325-78-2 (mono-hydrate)
38932-40-0 (mono-hydrochloride salt)
66905-57-5 (di-hydrate)
7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4- carboxylic acid
7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid
7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
AC1L1D8M
AC1L1Y1M
AC1O6OSE
AKOS004119846
Adcadina
Ades[prex
Alcephin
Alexin
Alsporin
Ambal
Anhydrous cefalexin
Anhydrous cephalexin
Aristosporin
Azabort
BB_NC-1052
BPBio1_000501
BRD-K90733503-002-03-6
BRN 0965503
BSPBio_000455
Bactopenor
Beliam
Biocef
C06895
C08099
C16H17N3O4S
CEX
CHEBI:3534
CHEBI:3535
CHEMBL1200544
CHEMBL1727
CID27447
CID62921
CID6560168
CPD-9227
CPD000338536
Carnosporin
Cefa-iskia
Cefablan
Cefacet
Cefadal
Cefadin
Cefadina
Cefalekey
Cefaleksin
Cefalessina
Cefalessina [DCIT]
Cefalexgobens
Cefalexin
Cefalexin (JP15)
Cefalexin Scand Pharm
Cefalexin Sodium
Cefalexin anhydrous
Cefalexin generics
Cefalexina
Cefalexina Northia
Cefalexina Richet
Cefalexina [INN-Spanish]
Cefalexine
Cefalexine [INN-French]
Cefalexinum
Cefalexinum [INN-Latin]
Cefalin
Cefalival
Cefaloto
Cefaseptin
Cefax
Ceffanex
Cefibacter
Ceflax
Ceforal
Cefovit
Celexin
Cepastar
Cepexin
Cephacillin
Cephalex von ct
Cephalexin (USP)
Cephalexin (anhydrous)
Cephalexin 1-hydrate
Cephalexin 1-wasser
Cephalexin [USAN:BAN]
Cephalexin anhydrous
Cephalexin hydrate
Cephalexin monohydrate
Cephalexin, (6R-(6alpha,7beta))-Isomer
Cephalexine
Cephalexinum
Cephalobene
Cephanasten
Cephaxin
Cephin
Cepol
Ceporex
Ceporex Forte
Ceporexin
Ceporexin-E
Ceporexine
Check
Cophalexin
Cusisporina-Cefalox
Céfalexine
D00263
 
D00906
DB00567
Domucef
Doriman
Durantel
Durantel DS
EINECS 239-773-6
Ed A-Ceph
Efemida
Erocetin
Factagard
Felexin
Fexin
HMS1569G17
HMS2051A04
HSDB 3022
Henina Oral
Ibilex
Ibrexin
Inphalex
KS-1134
Karilexina
Kefalospes
Keflet
Keflex
Keflex (TN)
Kefolan
Keforal
Keftab
Keftab (TN)
Kekrinal
Kidolex
L-Keflex
LS-149963
LS-173992
LS-174191
Lafarine
Larixin
Lenocef
Lexibiotico
Lilly 66873
Loisine
Lonflex
Lopilexin
Losporal
MLS000759527
Madlexin
Maksipor
Mamalexin
Mamlexin
Medolexin
Medoxine
MolPort-002-507-304
MolPort-006-823-789
NCGC00159522-02
NCGC00159522-03
Neokef
Neolexina
Noveol
Novolexin
Nufex
Oracef
Oriphex
Oroxin
Ortisporina
Ospexin
Palitrex
Panixine Disperdose
Panixine disperdose (TN)
Pectril
Prestwick0_000358
Prestwick1_000358
Prestwick2_000358
Prestwick3_000358
Prestwick_750
Prindex
Pyassan
Rilexine
Roceph
Roceph Distab
Rogevil
S 6437
SAM001246761
SMR000338536
SPBio_002376
SQ 20248
Sanaxin
Sartosona
Sencephalin
Sepexin
Servicef
Servispor
Sialexin
Sinthecillin
Sintolexyn
Sporicef
Sporidex
Syncl
Syncle
Synecl
Tepaxin
Theratrex
Tokiolexin
UNII-5SFF1W6677
UNII-OBN7UDS42Y
Uphalexin
Viosporine
Voxxim
Winlex
ZINC01530596
ZINC03830500
Zabytrex
Zozarine
cefalexin hydrate
cefalexin monohydrate
cefalexin.H2O
cephalexin
cephalexin.H2O
39
CiprofloxacinPhase 322185721-33-12764
Synonyms:
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
17850_FLUKA
3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)
33434_FLUKA
33434_RIEDEL
85721-33-1
AC-7613
AC1L1EEW
AKOS000269653
ARONIS020379
Alcon Cilox
BAS 06989041
BAY q 3939
BAY-Q-3939
BAYQ3939
BIDD:GT0205
BPBio1_000140
BRD-K04804440-311-02-3
BRN 3568352
BSPBio_000126
BSPBio_003344
Bacquinor
Baflox
Bay o 9867
Bay o 9867 (*Hydrochloride*)
Bay-09867
Baycip
Bernoflox
Bi-Cipro
Bio-0540
C05349
C17H18FN3O3
CAS-93107-08-5
CBMicro_048498
CCRIS 5241
CHEBI:100241
CHEMBL8
CID2764
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
CPF
CPFX
CRL-1605 & Ciprofloxacin
Ciflox
Cifloxin
Cilab
Ciloxan
Ciloxan (*Hydrochloride*)
Ciplus
Ciprecu
Ciprinol
Cipro
Cipro (*Hydrochloride*)
Cipro (TN)
Cipro I.V.
Cipro IV
Cipro XL
Cipro XR
Ciprobay
Ciprobay Uro
Ciprocinol
Ciprodar
Ciproflox
Ciprofloxacin
Ciprofloxacin (JAN/USP/INN)
Ciprofloxacin HCl
Ciprofloxacin Hydrchloride
Ciprofloxacin [USAN:INN:BAN]
Ciprofloxacin dihydrochloride
Ciprofloxacin hydrochloride
Ciprofloxacin monohydrochloride
Ciprofloxacina
Ciprofloxacine
Ciprofloxacine [INN-French]
Ciprofloxacino
 
Ciprofloxacino [INN-Spanish]
Ciprofloxacinum
Ciprofloxacinum [INN-Latin]
Ciprogis
Ciprolin
Ciprolon
Cipromycin
Ciproquinol
Ciprowin
Ciproxan
Ciproxin
Ciproxina
Ciproxine
Ciriax
Citopcin
Cixan
Corsacin
Cycin
Cyprobay
D00186
DB00537
DivK1c_000095
Eni
Fimoflox
Flociprin
Floxin
HMS1922E18
HMS2090O07
HMS2093I03
HMS500E17
HSDB 6987
IDI1_000095
Ipiflox
Italnik
KBio1_000095
KBio2_000642
KBio2_003210
KBio2_005778
KBio3_002846
KBioGR_001567
KBioSS_000642
LS-141563
Liposomal-ciprofloxacin
Loxan
MLS001336035
MolPort-000-819-654
NCGC00016959-01
NCGC00095058-01
NCGC00095058-02
NCGC00178128-01
NINDS_000095
NSC620634
Ocuflox
Oprea1_008239
Oprea1_313572
Prestwick0_000113
Prestwick1_000113
Prestwick2_000113
Prestwick3_000113
Probiox
Proflaxin
Proflox
Proksi 250
Proksi 500
Proquin XR
Quinolid
Quintor
Rancif
Roxytal
SMP1_000125
SMR000471901
SPBio_001474
SPBio_002065
SPECTRUM1503614
STK021082
Septicide
Sophixin Ofteno
Spectrum2_001567
Spectrum3_001872
Spectrum4_000874
Spectrum5_001089
Spectrum_000162
Spitacin
Superocin
UNII-5E8K9I0O4U
Unex
Velomonit
Zumaflox
ciprofloxacin
nchembio820-comp1
40
Folic AcidNutraceuticalPhase 3, Phase 2, Phase 1414359-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
41
NiacinNutraceuticalPhase 3, Phase 2, Phase 186259-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Nicacid
Nicamin
Nicangin
 
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
42FolateNutraceuticalPhase 3, Phase 2, Phase 14143
43Vitamin B3NutraceuticalPhase 3, Phase 2, Phase 1862
44
ornithineNutraceuticalPhase 36770-26-86262
Synonyms:
(+)-S-Ornithine
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-2,5-diaminovaleric acid
(S)-Ornithine
(S)-a,D-Diaminovalerate
 
(S)-a,D-Diaminovaleric acid
(S)-alpha,delta-Diaminovaleric acid
(S)-ornithine
(S)-α,δ-diaminovaleric acid
5-Amino-L-Norvaline
L-(-)-Ornithine
L-Ornithine
45COLANutraceuticalPhase 3, Phase 2, Phase 11824
46
NicotinamideNutraceuticalPhase 3, Phase 2, Phase 185898-92-0936
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
37321-14-5
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC-907/25014114
AC1L1ACZ
AC1Q4ZFV
AI3-02906
Acid amide
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra Brand of Niacinamide
Austrovit PP
B 3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin Amide
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
Hansamid
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
LS-2051
MLS000069714
Mediatric
Merck Brand of Niacinamide
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
NCGC00093354-03
NCGC00093354-04
NSC 13128
NSC13128
NSC27452
Nandervit-N
Niacevit
Niacinamide
Niacinamide (USP)
Niacinamide Astra Brand
Niacinamide Jenapharm Brand
Niacinamide Merck Brand
 
Niacinamide Pharmagenix Brand
Niacinamide [USAN]
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid Jenapharm
Nicotinsaureamid [German]
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
PP-Faktor
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix Brand of Niacinamide
Propamine A
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
SGCUT00176
SMR000058212
Savacotyl
UNII-25X51I8RD4
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin B 3
Vitamin B3
Vitamin H1
Vitamin PP
WLN: T6NJ CVZ
Witamina PP
ZINC00005878
b-Pyridinecarboxamide
beta-Pyridinecarboxamide
bmse000281
m-(Aminocarbonyl)pyridine
nchembio.154-comp4
nchembio.73-comp6
niacin - Vitamin B3
niacinamide
nicotinamide
pyridine-3-carboxamide
to_000073
vitamin PP
47TocopherolNutraceuticalPhase 3395
48
vitamin eNutraceuticalPhase 339259-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
49TocotrienolNutraceuticalPhase 3391
50
SorafenibPhase 2, Phase 1681284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum

Interventional clinical trials:

(show top 50)    (show all 378)
idNameStatusNCT IDPhase
1An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyApproved for marketingNCT02589717Phase 4
2First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based TherapyCompletedNCT00389155Phase 2, Phase 3
3Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder UrotheliumCompletedNCT00028756Phase 3
4Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial TractCompletedNCT00315237Phase 3
5Combination Chemotherapy in Treating Patients With Bladder CancerCompletedNCT00014534Phase 3
6Combination Chemotherapy in Treating Patients With Bladder CancerCompletedNCT00003701Phase 3
7Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.CompletedNCT00330499Phase 3
8Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3
9A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of UrineCompletedNCT02101931Phase 3
10Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder CancerCompletedNCT00004154Phase 3
11Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00003376Phase 3
12Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the UrotheliumCompletedNCT00014274Phase 2, Phase 3
13Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract CancerCompletedNCT00022191Phase 3
14High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder CancerCompletedNCT00003623Phase 3
15Surgery and BCG in Treating Patients With Bladder CancerCompletedNCT00002990Phase 3
16Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder CancerCompletedNCT00024349Phase 3
17Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder CancerCompletedNCT00002490Phase 3
18Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder CancerCompletedNCT00033436Phase 3
19S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder CancerCompletedNCT00445601Phase 3
20Eflornithine in Treating Patients With Bladder CancerCompletedNCT00003814Phase 3
21Selenium in Preventing Cancer Recurrence in Patients With Bladder CancerCompletedNCT00729287Phase 3
22Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder CancerCompletedNCT00406068Phase 2, Phase 3
23Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
24Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With CabazitaxelRecruitingNCT01668459Phase 2, Phase 3
25The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy [IMvigor130]RecruitingNCT02807636Phase 3
26Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)RecruitingNCT02853305Phase 3
27Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder CancerRecruitingNCT00146276Phase 3
28Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)RecruitingNCT01830231Phase 2, Phase 3
29A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial CancerRecruitingNCT02426125Phase 3
30Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT02502266Phase 2, Phase 3
31Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT02446600Phase 3
32Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT00719303Phase 3
33A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)RecruitingNCT01993979Phase 3
34Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder CancerRecruitingNCT00553345Phase 3
35Different Factors Affecting Patients With Newly Diagnosed Bladder CancerRecruitingNCT00553124Phase 3
36A Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerRecruitingNCT02632409Phase 3
37S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder CancerRecruitingNCT01224665Phase 3
38Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder CancerRecruitingNCT00553566Phase 3
39Quality of Life in Patients With Bladder CancerRecruitingNCT00553215Phase 3
40A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)RecruitingNCT02603432Phase 3
41I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras MutationsActive, not recruitingNCT02818725Phase 3
42Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerActive, not recruitingNCT00942331Phase 3
43Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder CancerActive, not recruitingNCT00867347Phase 3
44Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT00108745Phase 3
45Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT01167712Phase 3
46A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the UrotheliumActive, not recruitingNCT00949455Phase 2, Phase 3
474B951, Combination Chemotherapy in Treating Patients With Bladder CancerActive, not recruitingNCT00005047Phase 3
48Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder CancerActive, not recruitingNCT00054626Phase 3
49Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder CancerActive, not recruitingNCT00003725Phase 3
50A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBTActive, not recruitingNCT02563561Phase 3

Search NIH Clinical Center for Transitional Cell Carcinoma


Cochrane evidence based reviews: carcinoma, transitional cell

Genetic Tests for Transitional Cell Carcinoma

About this section

Anatomical Context for Transitional Cell Carcinoma

About this section

MalaCards organs/tissues related to Transitional Cell Carcinoma:

34
Kidney, Prostate, Lymph node, Lung, Ovary, Testes, Brain

Animal Models for Transitional Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

39 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.8CDKN2A, EGFR, ERBB2, FGFR3, HRAS, PTGS2
2MP:00107718.8CDH1, CDKN2A, EGFR, ERBB2, FGFR3, HRAS
3MP:00053818.6CDH1, CDKN2A, EGFR, EPHB2, ERBB2, FGFR3
4MP:00020068.6CDH1, CDKN2A, EGFR, ERBB2, FGFR3, HRAS
5MP:00030128.1BRINP1, CDH1, CDKN2A, EGFR, FGFR3, HRAS
6MP:00053678.0EGFR, EPHB2, FGFR3, HRAS, KRT7, PTGS2
7MP:00053847.5BRINP1, CDH1, CDKN2A, EGFR, EPHB2, ERBB2
8MP:00107686.9BRINP1, CDH1, CDKN2A, EGFR, EPHB2, ERBB2
9MP:00053786.8BRINP1, CDH1, CDKN2A, EGFR, EPHB2, ERBB2
10MP:00053766.6BRINP1, CDH1, CDKN2A, EGFR, ERBB2, FGFR3

Publications for Transitional Cell Carcinoma

About this section

Articles related to Transitional Cell Carcinoma:

(show top 50)    (show all 1176)
idTitleAuthorsYear
1
Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. (27453656)
2016
2
Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. (25619518)
2015
3
Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. (25646531)
2015
4
Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. (24890092)
2014
5
Long-term follow-up of transitional cell carcinoma of the bladder in childhood. (24035638)
2013
6
Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. (22759317)
2012
7
Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. (23018212)
2012
8
Relationships among MTHFR a1298c gene polymorphisms and methylation status of Dact1 gene in transitional cell carcinomas. (23244112)
2012
9
Ureterectomy and ureteral reimplatation for low-grade transitional cell carcinoma: is the laparoscopic approach feasible and effective? (21826883)
2011
10
Transitional cell carcinoma of the native urinary tract after kidney transplantation: recommendations following a long-term retrospective analysis. (21412138)
2011
11
Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men. (21046286)
2011
12
Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. (19457808)
2009
13
Transitional cell carcinoma of the urinary bladder: a clinicopathological study. (18946612)
2008
14
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. (18645275)
2008
15
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. (17293658)
2007
16
Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. (18092951)
2007
17
Glutathione S-transferase-P1 expression correlates with increased antioxidant capacity in transitional cell carcinoma of the urinary bladder. (17267100)
2007
18
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. (17011058)
2006
19
A case of transitional cell carcinoma of the renal pelvis with adenocarcinoma producing CEA and CA19-9]. (15518131)
2004
20
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. (14685796)
2004
21
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. (12576464)
2003
22
Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. (12670552)
2003
23
Leukemoid reaction associated with transitional cell carcinoma. (11908271)
2002
24
Risk factors for the development of bladder transitional cell carcinoma following surgery for transitional cell carcinoma of the upper urinary tract. (11490207)
2001
25
Genetic aberrations of NAT2 and chromosome 8: their association with progression in transitional cell carcinoma of the urinary bladder. (11598453)
2001
26
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. (11555602)
2001
27
Urinary cytokeratin 20 as a marker for transitional cell carcinoma. (10765100)
2000
28
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. (12840920)
2000
29
Detection of hematogenous micrometastasis in patients with transitional cell carcinoma. (10893639)
2000
30
Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. (10458411)
1999
31
Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma. (9818021)
1998
32
Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma. (10210109)
1998
33
Assessment of cell cycle-related elements p53, p21WAF1/Cip1, cyclin D1 and PCNA in a mixed transitional cell carcinoma and adenocarcinoma of the renal pelvis: a case report. (9614448)
1998
34
Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. (9477184)
1997
35
Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma. (9373912)
1997
36
Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. (9037279)
1997
37
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. (9187909)
1997
38
Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. (9275651)
1996
39
The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder. (8738404)
1996
40
Overexpression of C-erbB3 in transitional cell carcinoma of the ovary]. (8745489)
1995
41
Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. (1739130)
1992
42
c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder. (1364264)
1992
43
Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. (1377428)
1992
44
Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder. (1376008)
1992
45
Epidermal nevus with transitional cell carcinomas of the urinary tract. (1802914)
1991
46
Renal transitional cell carcinoma mimicking medullary sponge kidney. (2021801)
1991
47
ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-Guerin. (1710534)
1991
48
Correlation of the expression of A, B isoantigens with its precursor H antigen in transitional cell carcinoma and the clinical signification of the expression]. (2086062)
1990
49
Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. (2759734)
1989
50
Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa. (3121867)
1988

Variations for Transitional Cell Carcinoma

About this section

Cosmic variations for Transitional Cell Carcinoma:

8
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM550KRASurinary tract,bladder,carcinoma,undifferentiated carcinomac.181C>Gp.Q61E0

Copy number variations for Transitional Cell Carcinoma from CNVD:

6 (show top 50)    (show all 92)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1261361197500000205300000AmplificationLRRN2Urothelial cell carcinoma
2261411197500000205300000AmplificationMDM4Urothelial cell carcinoma
3261541197500000205300000LossUrothelial cell carcinoma
4426791038000006700000AmplificationPFKFB3Urothelial cell carcinoma
54967011110000000115400000LossANKK1Urothelial cell carcinoma
64967111110000000115400000LossDRD2Urothelial cell carcinoma
74967211110000000115400000LossNCAM1Urothelial cell carcinoma
84967311110000000115400000LossTTC12Urothelial cell carcinoma
952333111610000021600000LossPLEKHA7Urothelial cell carcinoma
1058688116920000070700000AmplificationCCND1Urothelial cell carcinoma
1158689116920000070700000AmplificationFGF19Urothelial cell carcinoma
1258690116920000070700000AmplificationFGF3Urothelial cell carcinoma
1358692116920000070700000AmplificationFGF4Urothelial cell carcinoma
1458694116920000070700000AmplificationORAOV1Urothelial cell carcinoma
1558695116920000070700000AmplificationTPCN2Urothelial cell carcinoma
1658889117070000074900000AmplificationUrothelial cell carcinoma
1758890117070000074900000AmplificationC11orf76Urothelial cell carcinoma
1858891117070000074900000AmplificationSHANK2Urothelial cell carcinoma
196448312128700000132349534LossFZD10Urothelial cell carcinoma
2069470125520000056300000AmplificationARHGAP9Urothelial cell carcinoma
2169471125520000056300000AmplificationDCTN2Urothelial cell carcinoma
2269472125520000056300000AmplificationGLI1Urothelial cell carcinoma
2369473125520000056300000AmplificationINHBCUrothelial cell carcinoma
2469474125520000056300000AmplificationKIF5AUrothelial cell carcinoma
2569475125520000061400000AmplificationCDK4Urothelial cell carcinoma
2669476125520000061400000AmplificationMETTL1Urothelial cell carcinoma
2769477125520000061400000AmplificationTSFMUrothelial cell carcinoma
2869795125630000061400000AmplificationFAM19A2Urothelial cell carcinoma
2969796125630000061400000AmplificationSLC16A7Urothelial cell carcinoma
3070900126600000069800000AmplificationCNOT2Urothelial cell carcinoma
3170901126600000069800000AmplificationCPMUrothelial cell carcinoma
3270902126600000069800000AmplificationIFNGUrothelial cell carcinoma
3370903126600000069800000AmplificationIL22Urothelial cell carcinoma
3470904126600000069800000AmplificationIL26Urothelial cell carcinoma
3570910126600000069800000AmplificationMDM2Urothelial cell carcinoma
3670911126600000069800000AmplificationTM4SF3Urothelial cell carcinoma
3771411126980000074100000AmplificationLGR5Urothelial cell carcinoma
3871412126980000074100000AmplificationTHAP2Urothelial cell carcinoma
3971413126980000074100000AmplificationTMEM19Urothelial cell carcinoma
4071414126980000074100000AmplificationTPH2Urothelial cell carcinoma
4171668127410000078700000AmplificationNAV3Urothelial cell carcinoma
4272907128750000091200000AmplificationKITLGUrothelial cell carcinoma
4373109129120000094800000AmplificationPLXNC1Urothelial cell carcinoma
4479797137780000086500000LossUrothelial cell carcinoma
4594764157040000073100000LossSDFR1Urothelial cell carcinoma
46109762172880000035600000AmplificationERBB2Urothelial cell carcinoma
47109763172880000035600000AmplificationTCAPUrothelial cell carcinoma
48123109186690000071300000LossUrothelial cell carcinoma
49123110186690000071300000LossSDCCAG33Urothelial cell carcinoma
50123111186690000071300000LossZADH2Urothelial cell carcinoma

Expression for genes affiliated with Transitional Cell Carcinoma

About this section
Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for genes affiliated with Transitional Cell Carcinoma

About this section

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
19.8CDH1, EGFR, ERBB2
29.7CDH1, HRAS, TP53
3
Show member pathways
9.7EPHB2, FGFR3, PTGS2
49.7EGFR, ERBB2, FGFR3
59.7EGFR, ERBB2, HRAS
69.6EGFR, FGFR3, HRAS
79.6CDH1, EGFR, ERBB2, TP53
89.5EGFR, ERBB2, PTGS2, TP53
99.5CDH1, EGFR, PTGS2, TP53
109.5EGFR, EPHB2, ERBB2, FGFR3
11
Show member pathways
9.5EGFR, ERBB2, FGFR3, TP53
129.5EGFR, ERBB2, HRAS, TP53
13
Show member pathways
9.5EGFR, ERBB2, HRAS, TP53
149.4CDH1, EGFR, ERBB2, HRAS
15
Show member pathways
9.4CDH1, EGFR, ERBB2, HRAS
169.4EGFR, HRAS, IFNA2, TP53
17
Show member pathways
9.4EGFR, ERBB2, HRAS, PTGS2
189.3CDKN2A, EGFR, HRAS, TP53
19
Show member pathways
9.3CDH1, ERBB2, HRAS, PTGS2, TP53
20
Show member pathways
9.2CDH1, EGFR, ERBB2, HRAS, TP53
219.2EGFR, ERBB2, FGFR3, HRAS, TP53
22
Show member pathways
9.2EGFR, ERBB2, FGFR3, HRAS, TP53
239.1EGFR, FGFR3, HRAS, IFNA2, TP53
24
Show member pathways
9.1CDKN2A, EGFR, ERBB2, HRAS, TP53
25
Show member pathways
8.9CDH1, EGFR, EPHB2, ERBB2, FGFR3, HRAS
26
Show member pathways
8.9CDH1, CDKN2A, EGFR, ERBB2, HRAS, TP53
278.5CDKN2A, EGFR, ERBB2, FGFR3, HRAS, PTGS2
288.3CDH1, CDKN2A, EGFR, ERBB2, FGFR3, HRAS
298.3CDH1, CDKN2A, EGFR, ERBB2, FGFR3, HRAS

GO Terms for genes affiliated with Transitional Cell Carcinoma

About this section

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical plasma membraneGO:00163248.8EGFR, ERBB2, UPK1A, UPK1B, UPK2, UPK3A

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1replicative senescenceGO:009039910.4CDKN2A, TP53
2regulation of phosphatidylinositol 3-kinase signalingGO:001406610.2EGFR, ERBB2, FGFR3
3ERBB2 signaling pathwayGO:003812810.0EGFR, ERBB2, HRAS
4positive regulation of MAP kinase activityGO:00434069.9EGFR, ERBB2, HRAS
5peptidyl-tyrosine phosphorylationGO:00181089.8EGFR, EPHB2, ERBB2, FGFR3
6positive regulation of epithelial cell proliferationGO:00506799.8EGFR, ERBB2, HRAS
7Ras protein signal transductionGO:00072659.6CDKN2A, HRAS, TP53
8epithelial cell differentiationGO:00308559.4UPK1A, UPK1B, UPK2, UPK3A
9cell cycle arrestGO:00070509.3BRINP1, CDKN2A, HRAS, TP53
10cell surface receptor signaling pathwayGO:00071668.4EGFR, ERBB2, HRAS, IFNA2, UPK1A, UPK1B

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:000471610.4EGFR, ERBB2
2phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.0EGFR, ERBB2, FGFR3
3protein phosphatase bindingGO:00199039.8EGFR, ERBB2, TP53
4protein tyrosine kinase activityGO:00047139.5EGFR, EPHB2, ERBB2, FGFR3

Sources for Transitional Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet